Vanguard Group Inc. increased its holdings in NeoGenomics, Inc. (NASDAQ:NEO) by 1.7% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,724,603 shares of the medical research company’s stock after acquiring an additional 44,820 shares during the period. Vanguard Group Inc. owned about 3.44% of NeoGenomics worth $24,413,000 at the end of the most recent quarter.
Other hedge funds have also added to or reduced their stakes in the company. Wrapmanager Inc. bought a new position in shares of NeoGenomics in the second quarter valued at approximately $109,000. KCG Holdings Inc. bought a new position in shares of NeoGenomics in the first quarter valued at approximately $118,000. OLD National Bancorp IN bought a new position in shares of NeoGenomics in the second quarter valued at approximately $141,000. Parkwood LLC bought a new position in shares of NeoGenomics in the second quarter valued at approximately $165,000. Finally, Principal Financial Group Inc. grew its holdings in shares of NeoGenomics by 2.5% in the first quarter. Principal Financial Group Inc. now owns 22,164 shares of the medical research company’s stock valued at $175,000 after acquiring an additional 545 shares in the last quarter. 80.35% of the stock is owned by institutional investors.
Shares of NeoGenomics, Inc. (NASDAQ NEO) opened at $8.59 on Tuesday. The stock has a market capitalization of $681.94, a price-to-earnings ratio of 171.80, a price-to-earnings-growth ratio of 6.78 and a beta of 0.84. NeoGenomics, Inc. has a 12-month low of $7.12 and a 12-month high of $11.63. The company has a current ratio of 2.37, a quick ratio of 2.21 and a debt-to-equity ratio of 0.60.
NeoGenomics (NASDAQ:NEO) last posted its earnings results on Wednesday, October 25th. The medical research company reported $0.01 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.01. The firm had revenue of $63.05 million for the quarter, compared to the consensus estimate of $63.11 million. NeoGenomics had a positive return on equity of 3.98% and a negative net margin of 4.78%. The business’s quarterly revenue was up 3.8% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.04 earnings per share. sell-side analysts forecast that NeoGenomics, Inc. will post 0.06 EPS for the current year.
Several equities analysts recently commented on the company. BidaskClub upgraded NeoGenomics from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, July 19th. Zacks Investment Research upgraded NeoGenomics from a “sell” rating to a “hold” rating in a research note on Saturday, July 29th. BTIG Research downgraded NeoGenomics from a “buy” rating to a “neutral” rating in a research note on Monday, September 11th. ValuEngine upgraded NeoGenomics from a “sell” rating to a “hold” rating in a research note on Monday, August 7th. Finally, Janney Montgomery Scott reiterated a “buy” rating on shares of NeoGenomics in a research note on Thursday, October 26th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and four have issued a buy rating to the company. NeoGenomics has an average rating of “Hold” and an average target price of $10.33.
NeoGenomics Company Profile
NeoGenomics, Inc is an operator of a network of cancer-focused genetic testing laboratories. The Company operates in Laboratory Testing Segment. This segment delivers testing services to hospitals, pathologists, oncologists, other clinicians and researchers. It has laboratory locations in Ft. Myers and Tampa, Florida; Aliso Viejo, Fresno, Irvine, and West Sacramento, California; Houston, Texas and Nashville, and Tennessee.
Receive News & Ratings for NeoGenomics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.